High-Priced PDPs Dominate 2021 Insulin Demo
As Medicare Advantage and Part D sponsors started promoting their offerings during the 2021 Annual Election Period that began on Oct. 15, several major insurers notably mentioned their participation in the first year of the CMS Part D Senior Savings Model (SSM). Perhaps the Trump administration’s most tangible action on insulin costs, the model is intended to reduce Medicare expenditures and improve care quality, but the expense to seniors will vary by plan type and region, observes a new analysis from Avalere Health.
Introduced through the CMS Center for Medicare & Medicaid Innovation (CMMI) in March, the five-year model is intended to lower out-of-pocket costs for diabetic seniors by featuring “predictable” copayments of no more than $35 for a broad set of insulins beginning in 2021 (RMA 3/19/20, p. 1).
Related Posts

Medicaid Beneficiaries Are Unequally Served by Non-Emergency Medical Transportation
READ MORE
With Final RADV Rule Out, MAOs Are Advised to Clean Up Risk Adjustment Practices
READ MORE